Update from PTC Therapeutics
In a press release on February 19, 2026, PTC Therapeutics announced that a Type C meeting with FDA held in December 2025 to discuss the vatiquinone Friedreich’s ataxia program. FDA indicated that an additional study would be necessary to support NDA resubmission, and meeting minutes stated that this could be an open-label study with a natural history control group.
Learn more about PTC Therapeutics’ vatiquinone program on our pipeline page.
